<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>60(11)</volume><submitter>Roth NJ</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Nanofiltration entails the filtering of protein solutions through membranes with pores of nanometric sizes that have the capability to effectively retain a wide range of viruses.&lt;h4>Study design and methods&lt;/h4>Data were collected from 754 virus validation studies (individual data points) by Plasma Protein Therapeutics Association member companies and analyzed for the capacity of a range of nanofilters to remove viruses with different physicochemical properties and sizes. Different plasma product intermediates were spiked with viruses and filtered through nanofilters with different pore sizes using either tangential or dead-end mode under constant pressure or constant flow. Filtration was performed according to validated scaled-down laboratory conditions reflecting manuf</pubmed_abstract><journal>Transfusion</journal><pagination>2661-2674</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7754444</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.</pubmed_title><pmcid>PMC7754444</pmcid><pubmed_authors>Gajardo R</pubmed_authors><pubmed_authors>Flechsig E</pubmed_authors><pubmed_authors>Poelsler G</pubmed_authors><pubmed_authors>Roberts P</pubmed_authors><pubmed_authors>Moretti E</pubmed_authors><pubmed_authors>More J</pubmed_authors><pubmed_authors>Jorquera JI</pubmed_authors><pubmed_authors>Kreil TR</pubmed_authors><pubmed_authors>Dichtelmuller HO</pubmed_authors><pubmed_authors>Roth NJ</pubmed_authors><pubmed_authors>Moscardini M</pubmed_authors><pubmed_authors>Misztela D</pubmed_authors><pubmed_authors>Fabbrizzi F</pubmed_authors><pubmed_authors>Groner A</pubmed_authors><pubmed_authors>Gustafson M</pubmed_authors><pubmed_authors>Wieser A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.</name><description>&lt;h4>Background&lt;/h4>Nanofiltration entails the filtering of protein solutions through membranes with pores of nanometric sizes that have the capability to effectively retain a wide range of viruses.&lt;h4>Study design and methods&lt;/h4>Data were collected from 754 virus validation studies (individual data points) by Plasma Protein Therapeutics Association member companies and analyzed for the capacity of a range of nanofilters to remove viruses with different physicochemical properties and sizes. Different plasma product intermediates were spiked with viruses and filtered through nanofilters with different pore sizes using either tangential or dead-end mode under constant pressure or constant flow. Filtration was performed according to validated scaled-down laboratory conditions reflecting manuf</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2025-04-26T23:57:44.291Z</modification><creation>2021-02-20T16:51:12Z</creation></dates><accession>S-EPMC7754444</accession><cross_references><pubmed>32815181</pubmed><doi>10.1111/trf.16022</doi></cross_references></HashMap>